ArticleJournal of virology2026
NFX1-123 is required for keratinocyte differentiation and HPV 16 DNA maintenance in early and persistent infection models.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Persistent high-risk human papillomavirus (HR HPV) infections cause nearly 5% of cancers worldwide, including cervical and oropharyngeal cancers. HR HPVs sustain long-term infections in stratified epithelial tissues by maintaining copies of viral genomes in basal keratinocytes and utilizing the cellular differentiation processes in the upper layers to coordinate key steps in the viral life cycle. We have demonstrated previously that the endogenous host protein NFX1-123 bound directly to the HR HPV type 16 oncoprotein E6 (16E6), and that this partnership increased keratinocyte proliferation and differentiation, two processes that are both required for persistent HPV 16 infections. As there is a range of endogenous expression of NFX1-123 in normal basal keratinocytes, we aimed to investigate the role of NFX1-123 abundance on the initiation and persistence of HPV 16 infections. In this study, we utilized keratinocytes with overexpressed, endogenous, or reduced levels of NFX1-123 and infected these cells with an HPV 16 quasivirus (Qsv) to interrogate changes to keratinocyte growth and viral DNA copy numbers with NFX1-123 modulation. Keratinocytes with reduced NFX1-123 had blunted differentiation and stratification in raft cultures, and this correlated with decreased HPV 16 Qsv DNA copies. Similarly, when we reduced NFX1-123 in W12E cells, a cervical cell line harboring episomal HPV 16 genomes, we saw a decrease in raft culture differentiation and thickness, and fewer viral genome copies compared to W12E cells with endogenous NFX1-123. These findings indicate the importance of NFX1-123 on the initiation and maintenance of HPV 16 infections that may persist and progress to cancer.IMPORTANCEA high-risk human papillomavirus (HPV) infection that persists for decades is the biggest risk factor for the development of cervical and other HPV-associated cancers. The ability of HPV to maintain its genome and persist in stratified epithelium is dependent on its partnership with host proteins and its co-opting of cellular pathways. Here, we investigate how the abundance of HPV 16's host protein partner NFX1-123 affects viral genome maintenance and replication in monolayer and three-dimensional cultures, modeling both early and persistent infection. This study reveals that NFX1-123 is required for keratinocyte differentiation and stratification in raft cultures, and the disruption of these processes significantly impedes the ability of HPV 16 to maintain its episomal genome at consistent copy numbers. These findings indicate the importance of NFX1-123 for the persistence of HPV 16 infections and encourage further investigation of NFX1-123 as a potential therapeutic target in HPV 16-positive cancers and precancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.